Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO

INTRODUCTION: Dolutegravir (DTG) 50 mg once daily was superior to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily through Week 48, with 90% vs. 83% of participants achieving HIV RNA 50 c/mL (p=0.025) [1]. We present data through Week 96. MATERIAL AND METHODS: FLAMINGO is a multicentre, randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina, Jean-Michel, Clotet, Bonaventura, van Lunzen, Jan, Lazzarin, Adriano, Cavassini, Matthias, Henry, Keith, Kulagin, Valeriv, Givens, Naomi, Brennan, Clare, de Oliveira, Carlos Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Oral Presentation – Abstract O153
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224885/
https://www.ncbi.nlm.nih.gov/pubmed/25393999
http://dx.doi.org/10.7448/IAS.17.4.19490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224885/
https://www.ncbi.nlm.nih.gov/pubmed/25393999
http://dx.doi.org/10.7448/IAS.17.4.19490

Ejemplares similares